Identification and Targeting of Thomsen–Friedenreich and IL1RAP Antigens on Chronic Myeloid Leukemia Stem Cells Using Bi-Specific Antibodies-Reference-Cited by-同舟云学术

Identification and Targeting of Thomsen–Friedenreich and IL1RAP Antigens on Chronic Myeloid Leukemia Stem Cells Using Bi-Specific Antibodies

Published:2021-01 Issue: Volume:Volume 14 Page:609-621
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Eldesouki Raghda^ORCID,Wu Chengxiang,Saleh Fayez M,Mohammed Eman Abdel-Moemen,Younes Soha^ORCID,Hassan Naglaa Elsayed,Brown Theresa C,Alt Eckhard U^ORCID,Robinson James E,Badr Fouad Mohamed,Braun Stephen E^ORCID

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference47 articles.

1. Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review

2. Do we need more drugs for chronic myeloid leukemia?

3. Leukemia stem cells: the root of chronic myeloid leukemia

4. The chronic myeloid leukemia stem cell: stemming the tide of persistence

5. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors;Expert Opinion on Pharmacotherapy;2024-01-22

2. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia;International Journal of Biological Sciences;2024

3. CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors;Frontiers in Immunology;2023-10-17

4. IL-1RAP, a Key Therapeutic Target in Cancer;International Journal of Molecular Sciences;2022-11-29

5. Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review;F1000Research;2022-02-09